Published in J Antimicrob Chemother on October 05, 2016
Roles of the intestinal microbiota in pathogen protection. Clin Transl Immunology (2017) 0.75
Microbial Shifts in the Intestinal Microbiota of Salmonella Infected Chickens in Response to Enrofloxacin. Front Microbiol (2017) 0.75
Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell (2004) 29.32
Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell (2009) 20.29
Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity (2010) 8.90
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis (2007) 8.65
Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A (2011) 6.16
Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife (2013) 5.49
Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest (2010) 4.95
The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med (2015) 3.01
Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol (2013) 2.89
Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol (2007) 2.83
Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep (2012) 2.83
A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology (2010) 2.38
Antibiotics in early life alter the gut microbiome and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes. PLoS One (2015) 1.63
Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis (2012) 1.60
Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis (2006) 1.59
Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol (2013) 1.35
Antibiotics, microbiota, and immune defense. Trends Immunol (2012) 1.33
Loss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection With Oral Vancomycin Compared With Metronidazole. J Infect Dis (2015) 1.04
Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole. PLoS One (2013) 1.03
Lactobacillus reuteri and Escherichia coli in the human gut microbiota may predict weight gain associated with vancomycin treatment. Nutr Diabetes (2013) 0.88
Determining the Long-term Effect of Antibiotic Administration on the Human Normal Intestinal Microbiota Using Culture and Pyrosequencing Methods. Clin Infect Dis (2015) 0.88
Differences of the Fecal Microflora With Clostridium difficile Therapies. Clin Infect Dis (2015) 0.81
Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother (2012) 0.79
Risk Factors and Outcomes for Bloodstream Infections Secondary to Clostridium difficile Infection. Antimicrob Agents Chemother (2015) 0.78